Lundbeck dans l'actualité
Spécialisé dans les maladies cérébrales
Tamtam a trouvé 20 articles récents sur Lundbeck.
- Barclays raises Lundbeck price target to 50 Danish kroner (48), reiterates equal weight - BN
- Cradle & Lundbeck: Partnering on Biotherapeutics and AI
- Ugens danske Vindere og tabere: Torm, Norden og Lundbeck topper
- Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress
- Lundbeck moves from rebuilding to “scaling phase”, Jefferies says
- Lundbeck vil præsentere præklinisk data om epilepsikandidat i weekenden
- AprilBio's APB-A1 Development Resumes at Lundbeck with Shift to Neurological Diseases; Licensing Deal Value Intact
- H. Lundbeck (CPSE:HLUN B) After Strong Q2 Results Is The Stock A Bargain Or Priced Right
- Eversana rolls out expanded AI agency platform with client Lundbeck going all-in
- Secret Novo-Lundbeck collaboration helped seal Swedish CNS deal: "You have to move quickly"
- H. Lundbeck (CPSE:HLUN A) - Analyse des actions
- Lundbeck expands AI partnership for commercialization in the US
- Lundbeck gains EU orphan status for anti‑ACTH antibody
- Lundbeck receives coveted status for drug candidate in the EU
- Lundbeck, Eversana Expand AI Commercialization Partnership
- Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
- Lundbeck And Eversana Announce Strategic Partnership
- Lundbeck and EVERSANA partner to advance AI-powered commercialization
- Lundbeck får eftertragtet status til lægemiddelkandidat i EU
- Lundbeck and EVERSANA Announce Strategic Partnership to Advance AI-Powered Commercialization
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Lundbeck ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires